Concepedia

Publication | Open Access

Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)

DOIFull Paper Access

23

Citations

0

References

2017

Year

Cristina Saura, Evandro de Azambuja, Dominik Hlauschek, Mafalda Oliveira, Dimitrios Zardavas, Anita Jallitsch-Halper, Lorena de la Peña, Paolo Nucíforo, Alberto Ballestrero, Monica Fornier,
Annals of Oncology

No additional data available for this publication yet. Check back later!